Cargando…
Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk
The integrated European project, EU-ToxRisk, proudly sees itself as “flagship” exploring new alternative-to-animal approaches to chemical safety evaluation. It promotes mechanism-based toxicity testing and risk assessment according to the principles laid down for toxicology for the twenty-first cent...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830874/ https://www.ncbi.nlm.nih.gov/pubmed/27017488 http://dx.doi.org/10.1007/s00204-016-1698-7 |
_version_ | 1782426965397995520 |
---|---|
author | Daneshian, Mardas Kamp, Hennicke Hengstler, Jan Leist, Marcel van de Water, Bob |
author_facet | Daneshian, Mardas Kamp, Hennicke Hengstler, Jan Leist, Marcel van de Water, Bob |
author_sort | Daneshian, Mardas |
collection | PubMed |
description | The integrated European project, EU-ToxRisk, proudly sees itself as “flagship” exploring new alternative-to-animal approaches to chemical safety evaluation. It promotes mechanism-based toxicity testing and risk assessment according to the principles laid down for toxicology for the twenty-first century. The project was officially launched in January 2016 with a kickoff meeting in Egmond aan Zee, the Netherlands. Over 100 scientists representing academia and industry as well as regulatory authorities attended the inaugural meeting. The project will integrate advances in in vitro and in silico toxicology, read-across methods, and adverse outcome pathways. EU-ToxRisk will continue to make use of the case study strategy deployed in SEURAT-1, a FP7 initiative ended in December 2015. Even though the development of new non-animal methods is one target of EU-ToxRisk, the project puts special emphasis on their acceptance and implementation in regulatory contexts. This €30 million Horizon 2020 project involves 38 European partners and one from the USA. EU-ToxRisk aims at the “development of a new way of risk assessment.” |
format | Online Article Text |
id | pubmed-4830874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-48308742016-04-22 Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk Daneshian, Mardas Kamp, Hennicke Hengstler, Jan Leist, Marcel van de Water, Bob Arch Toxicol Editorial The integrated European project, EU-ToxRisk, proudly sees itself as “flagship” exploring new alternative-to-animal approaches to chemical safety evaluation. It promotes mechanism-based toxicity testing and risk assessment according to the principles laid down for toxicology for the twenty-first century. The project was officially launched in January 2016 with a kickoff meeting in Egmond aan Zee, the Netherlands. Over 100 scientists representing academia and industry as well as regulatory authorities attended the inaugural meeting. The project will integrate advances in in vitro and in silico toxicology, read-across methods, and adverse outcome pathways. EU-ToxRisk will continue to make use of the case study strategy deployed in SEURAT-1, a FP7 initiative ended in December 2015. Even though the development of new non-animal methods is one target of EU-ToxRisk, the project puts special emphasis on their acceptance and implementation in regulatory contexts. This €30 million Horizon 2020 project involves 38 European partners and one from the USA. EU-ToxRisk aims at the “development of a new way of risk assessment.” Springer Berlin Heidelberg 2016-03-26 2016 /pmc/articles/PMC4830874/ /pubmed/27017488 http://dx.doi.org/10.1007/s00204-016-1698-7 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Editorial Daneshian, Mardas Kamp, Hennicke Hengstler, Jan Leist, Marcel van de Water, Bob Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk |
title | Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk |
title_full | Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk |
title_fullStr | Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk |
title_full_unstemmed | Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk |
title_short | Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk |
title_sort | highlight report: launch of a large integrated european in vitro toxicology project: eu-toxrisk |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830874/ https://www.ncbi.nlm.nih.gov/pubmed/27017488 http://dx.doi.org/10.1007/s00204-016-1698-7 |
work_keys_str_mv | AT daneshianmardas highlightreportlaunchofalargeintegratedeuropeaninvitrotoxicologyprojecteutoxrisk AT kamphennicke highlightreportlaunchofalargeintegratedeuropeaninvitrotoxicologyprojecteutoxrisk AT hengstlerjan highlightreportlaunchofalargeintegratedeuropeaninvitrotoxicologyprojecteutoxrisk AT leistmarcel highlightreportlaunchofalargeintegratedeuropeaninvitrotoxicologyprojecteutoxrisk AT vandewaterbob highlightreportlaunchofalargeintegratedeuropeaninvitrotoxicologyprojecteutoxrisk |